Companies

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results

Published December 16, 2024

NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") AVXL is a clinical-stage biopharmaceutical company that focuses on creating innovative treatments for several serious conditions. These include Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental disorders, neurodegenerative diseases, and rare conditions such as Rett syndrome, alongside other central nervous system (CNS) ailments.

On December 23, 2024, Anavex will release its financial results for the fiscal year that ended on September 30, 2024. This announcement is particularly significant for investors and stakeholders following the company's progress in developing therapeutic solutions.

Management has scheduled a conference call for December 23 at 8:30 am ET. During this call, the management team will discuss the financial results and provide insights into the company's growth strategy. After their presentation, there will be an opportunity for a question-and-answer session where participants can engage with the management team.

Webcast / Conference Call Information:

Individuals interested in attending the conference call can access a live webcast through Anavex's official website at www.anavex.com.

For those wishing to join by phone, the call can be accessed by dialing 1 929 205 6099 in the U.S. Participants will need the Meeting ID# 814 6482 4038 and the reference passcode 336064. Additionally, a replay of this conference call will be available on Anavex's website for a period of up to 30 days for those who cannot attend the live session.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (AVXL) is known for its commitment to developing novel therapeutics aimed at treating various CNS disorders. Their leading drug candidate, ANAVEX®2-73 (blarcamesine), has undergone successful clinical trials, including a Phase 2a and a Phase 2b/3 for Alzheimer's disease. It has also completed a Phase 2 proof-of-concept trial for dementia related to Parkinson's disease, as well as both Phase 2 and Phase 3 trials for adult patients, and a Phase 2/3 trial for pediatric patients suffering from Rett syndrome. This orally administered drug is designed to restore cellular balance by targeting specific receptors. Preclinical studies have shown its potential to halt or reverse the course of Alzheimer's disease, and it has also demonstrated several beneficial effects in animal models.

Moreover, Anavex's ANAVEX®3-71, which simultaneously targets receptors associated with Alzheimer's disease, shows promise in preclinical trials for addressing cognitive dysfunction and related pathologies. This candidate has exhibited advantages regarding mitochondrial problems and neuroinflammation. More information about the company can be found at www.anavex.com or by connecting with them on social media platforms such as Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

It is essential to note that any statements made in this release that are not strictly historical should be interpreted as forward-looking statements. These statements are based on current expectations and involve various risks and uncertainties. Actual events or results may significantly differ from those projected due to these factors. Readers are advised not to place excessive reliance on these forward-looking statements, as they reflect conditions as of the date of this release. Anavex Life Sciences Corp. will not revise or update this information following future events or circumstances.

For Further Information:

Anavex Life Sciences Corp.

Research & Business Development

Toll-free: 1-844-689-3939

Email: [email protected]

Anavex, pharmaceutical, biotechnology